FDA Guides On COVID-19 Obstacles To ANDA Studies
Protecting Participants In Bioequivalence Studies Should Be Top Priority
Executive Summary
Specific guidance for ANDA sponsors on bioequivalence studies during the COVID-19 pandemic has been published by the US FDA.
You may also be interested in...
FDA Alert Curbs Enthusiasm For Hydroxychloroquine And Chloroquine
A drug safety communication published by the US FDA over hydroxychloroquine and chloroquine has cooled hopes that the drugs could be used as key treatments to address the coronavirus pandemic.
FDA Goes Straight To Final Guidance For Generic Chloroquine
Product-specific guidances for generic versions of chloroquine and hydroxychloroquine have been issued by the FDA. Final guidance for chloroquine has been published without a draft version due to the need for speedy action amid the COVID-19 outbreak.
FDA Scales Back Domestic Inspections Due To Coronavirus
After postponing foreign inspections, the US FDA has further decided to scale back domestic inspections due to the coronavirus outbreak.